Literature DB >> 15133502

Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.

Julie A Clapperton1, Isaac A Manke, Drew M Lowery, Timmy Ho, Lesley F Haire, Michael B Yaffe, Stephen J Smerdon.   

Abstract

Germline mutations in the BRCA1 tumor suppressor gene often result in a significant increase in susceptibility to breast and ovarian cancers. Although the molecular basis of their effects remains largely obscure, many mutations are known to target the highly conserved C-terminal BRCT repeats that function as a phosphoserine/phosphothreonine-binding module. We report the X-ray crystal structure at a resolution of 1.85 A of the BRCA1 tandem BRCT domains in complex with a phosphorylated peptide representing the minimal interacting region of the DEAH-box helicase BACH1. The structure reveals the determinants of this novel class of BRCA1 binding events. We show that a subset of disease-linked mutations act through specific disruption of phospho-dependent BRCA1 interactions rather than through gross structural perturbation of the tandem BRCT domains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133502     DOI: 10.1038/nsmb775

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  114 in total

1.  Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains.

Authors:  Maria Victoria E Botuyan; Yves Nominé; Xiaochun Yu; Nenad Juranic; Slobodan Macura; Junjie Chen; Georges Mer
Journal:  Structure       Date:  2004-07       Impact factor: 5.006

2.  BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Authors:  Reena Shakya; Latarsha J Reid; Colleen R Reczek; Francesca Cole; Dieter Egli; Chyuan-Sheng Lin; Dirk G deRooij; Steffen Hirsch; Kandasamy Ravi; James B Hicks; Matthias Szabolcs; Maria Jasin; Richard Baer; Thomas Ludwig
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

Review 3.  BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies.

Authors:  Seth M Dever; E Railey White; Matthew C T Hartman; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

4.  Requirement for the phospho-H2AX binding module of Crb2 in double-strand break targeting and checkpoint activation.

Authors:  Steven L Sanders; Ahmad R Arida; Funita P Phan
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

5.  Molecular basis of BACH1/FANCJ recognition by TopBP1 in DNA replication checkpoint control.

Authors:  Charles Chung Yun Leung; Zihua Gong; Junjie Chen; J N Mark Glover
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

Review 6.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.

Authors:  Mary Ellen Moynahan; Maria Jasin
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03       Impact factor: 94.444

7.  A computational method for the analysis and prediction of protein:phosphopeptide-binding sites.

Authors:  Brian A Joughin; Bruce Tidor; Michael B Yaffe
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

8.  BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1.

Authors:  Jianqiu Zou; Deli Zhang; Guang Qin; Xiangming Chen; Hongmin Wang; Dong Zhang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

10.  Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.

Authors:  Yang Shen; Liang Tong
Journal:  Biochemistry       Date:  2008-05-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.